(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2020³â Á¦72Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ : 2020-10-18±³À°ÀÏÀÚ : 2020-10-18
±³À°Àå¼Ò : ¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ (¿ÀÇÁ¶óÀÎ: ¼¿ï µå·¡°ï½ÃƼ È£ÅÚ 2Ãþ ÇѶóȦ ¿Ü)
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ) 2020³â Á¦72Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãß°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ¼´ëÇå
¿¬¶ôó : 02-3473-0284
À̸ÞÀÏ :
kda@derma.or.kr ±³À°Á¾·ù : ÇǺΰú
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 4Á¡ / Çʼö 2Á¡)
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 22 ½Ã°£ 53ºÐ
¼¼ºÎ¼ö°·á : 500,000¿ø
ºñ°í ¿ÀÇÁ¶óÀÎ: Á¤È¸¿ø 70,000 ÁØȸ¿ø 30,000 / ¿Â¶óÀÎ: Á¤È¸¿ø 50,000 ÁØȸ¿ø20,000 ºñȸ¿ø 500,000 / ¸¸65¼¼ ÀÌ»ó ¸éÁ¦
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 15:00~15:25 Laser therapy ±è¿ø¼®(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 15:25~15:30 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 15:30~15:55 Scalpel surgery and other procedures ³ë¹Ì·É(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 15:55~16:00 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 12:30~12:33 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 12:33~13:20 Occupational dermatoses in Korea ÀÌÁØ¿µ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 13:20~13:30 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 15:00~15:05 Introduction Chair()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 15:05~15:35 Leprosy ±èÁ¾ÇÊ(Çѱ¹ÇѼ¾º¹ÁöÇùȸ)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 15:35~15:50 Pathology of leprosy À̼º¹ü(°¡Å縯ÀÇ´ë º´¸®Çаú)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 15:50~16:00 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 16:00~16:02 Introduction Chair()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 16:02~16:18 Pathogenesis ±èÇý¿ø(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 16:18~16:34 Optimal medical treatment of hidradenitis suppurativa : When & How? ÀÌÈñÁ¤(Â÷ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 16:34~16:50 Surgical management ±èÈƼö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 16:50~17:00 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 13:30~13:35 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 13:35~14:35 Death is an extiction or moving? (60min) Á¤Çöä(Çѱ¹Á×À½ÇÐȸ ÀÌ»ç/Àü ¼¿ïÀÇ´ë ³»°úÇб³½Ç)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 14:35~14:40 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 13:30~13:50 Normal histology of the skin À̽ÂÈ£(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 13:50~14:20 Pattern diagnosis of skin diseases À̼®Á¾(°æºÏÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 14:20~14:30 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 15:40~15:55 Human sample handling ¿ÂÁ¤À±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 15:55~16:00 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 16:00~16:15 Essential tips on skin tissue staining ½Å±âÇõ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 16:15~16:20 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 16:20~16:35 Primary cell culture isolated human skin ¼Áö¸í(KAIST)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 16:35~16:40 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 16:40~16:55 What to include in IRB for research using human samples ¿À¿µÁÖ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 16:55~17:00 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 12:30~12:35 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 12:35~13:20 On Prevention of Medical Disputes and Alternative Dispute Resolution of Medical Disputes ±è°æ·Ê(Çѱ¹¼ÒºñÀÚ¿ø)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 13:20~13:30 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 16:00~16:05 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 16:05~16:50 Clinical Ethics for Dermatologists ±è¿ÁÁÖ(¼¿ïÀÇ´ë Àι®ÀÇÇб³½Ç)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 16:50~17:00 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 08:00~08:20 Connective tissue and bullous disease ÀüÁöÇö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 08:20~08:40 Pigmentary, endocrine and metabolic disease ¿ìÀ¯¸®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 08:40~09:05 Urticaria, Erythematous and vascular disease ¹ÚÀºÁÖ(ÇѸ²ÀÇ´ë)
ÈÞ½Ä 10¿ù 18ÀÏ ¹éµÎ 1 09:05~09:10 Break ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 09:10~09:30 Benign and malignant tumor of epidermis ±èÈƼö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 09:30~09:50 Appendageal tumor, tumor of melanocyte, tumor of dermis and subcutaneous fat, cutaneous lymphoma ±èÈñÁÖ(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 09:50~10:10 Dermatoses due to physical forces and disease of subcutaneous fat ÀÌÁöÇý(°¡Å縯ÀÇ´ë)
ÈÞ½Ä 10¿ù 18ÀÏ ¹éµÎ 1 10:10~10:15 Break ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 10:15~10:40 Laser and cosmetic dermatology ½ÅÁ¤¿ø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 1 10:40~11:00 Dermatosurgery ÃÖÁö¿õ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 08:00~08:03 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 08:03~08:48 Embracing a new horizon in treating palmoplantar pustulosis Á¤±âÇå(°æÈñÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 08:48~09:00 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 11:10~11:13 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 11:13~11:58 Is CompleteSkin Clearance the Only answer for PsoriasisPatients? Á¶¼ºÁø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 1+2 11:58~12:10 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 10:00~10:03 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 10:03~10:23 Acne treatment and Epiduo Forte¢ç ±èÁ¤Àº(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 10:23~10:43 Soolantra for Rosacea Á¤º¸¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 10:43~10:50 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 12:30~12:33 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 12:33~13:13 What could be the BEST OPTION IF YOU WERE A PATIENT with Psoriasis? ±èűÕ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 13:13~13:20 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 13:20~13:23 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 13:23~13:53 Long-term efficacy and safety of Avodart ±èµµ¿µ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 13:53~14:00 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 14:00~14:03 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 14:03~14:33 Proven efficacy and safety of finasteride in androgenic alopecia ¹Úº´Ã¶(´Ü±¹ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 14:33~14:40 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 15:00~15:03 Introduction ()
±³À°½Ã°£ 10¿ù 18ÀÏ ¹éµÎ 2 15:03~15:33 Onychomycosis, Diagnosis and treatment based on Korean guide line ¼Çö¹Î(ÇѾçÀÇ´ë)
ÈÞ½Ä 10¿ù 18ÀÏ ¹éµÎ 2 15:33~15:40 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 10:00~10:05 Overview chair()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 10:05~10:20 Th1 cells and Thassociated uncommon skin diseases (sarcoidosis) ±èÁ¾ÈÆ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 10:20~10:35 Th2 cells and Thassociated uncommon skin diseases (eosinophilic diseases) À̵¿ÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 10:35~10:50 Th17 cells and Th17-associated uncommon skin diseases (pityriasis rubra pilaris, hidradenitis suppurativa) ÃÖÁ¾¿ø(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 10:50~11:00 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 12:30~12:35 Overview chair()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 12:35~12:50 Recent advances in understanding rosacea pathogenesis ¹Ú±Í¿µ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 12:50~13:05 New data for better care of rosacea ½Å¹Î°æ(°æÈñÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 13:05~13:20 An approach to clinical variants of rosacea Á¤½ÂÇö(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 13:20~13:30 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 13:30~13:35 Overview Chair()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 13:35~13:45 Basic concept of Wound Healing ¿øÁ¾Çö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 13:45~14:00 Dressing Materials Part 1 Á¶¼ºÁø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 14:00~14:10 Dressing Materials Part 2 ¿Àº´È£(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 14:10~14:20 Emerging therapy for Scar Management ±è¿ø¼®(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 14:20~14:30 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 15:00~15:15 Skin rash related to COVID-19 infection ¹æöȯ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 15:15~15:30 Personal protective equipments (face mask, eye shield)-induced rash ÃÖ¼±¿µ(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 15:30~15:45 Contact dermatitis due to handwashing and glove Á¤ÇýÁ¤(±¹¸³Áß¾ÓÀÇ·á¿ø)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 15:45~16:00 Q&A ()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 16:00~16:03 Overview Chair()
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 16:03~16:15 Differential diagnosis of nail diseases based on clinical features ÀÌ°æÈ£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 16:15~16:27 Histopathology of inflammatory nail diseases ¹®Á¦È£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 16:27~16:39 Tumors specific in nail apparatus À̵¿À±(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 16:39~16:51 Hereditary and congenital nail diseases À̽ÂÈ£(µ¿±¹ÀÇ´ë)
±³À°½Ã°£ 10¿ù 18ÀÏ ÇѶó 3 16:51~17:00 Q&A ()